张继东 荣朝 胡娟 孙绪举



[摘要] 目的 探討地特胰岛素联合利拉鲁肽对二甲双胍无效的老年2型糖尿病(T2DM)的作用。 方法 回顾性分析2017年10月—2019年4月华中科技大学医院收治的127例对二甲双胍无效的老年T2DM患者的临床资料,根据治疗方法分为A组(采用地特胰岛素治疗40例)、B组(采用利拉鲁肽治疗41例)和C组(采用地特胰岛素联合利拉鲁肽治疗46例)。比较三组患者治疗前后体重指数(BMI)、空腹血糖(FPG)、餐后2 h血糖(2hPBG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)变化及不良反应。 结果 治疗前三组BMI、FPG、2hPBG、HbA1c、HOMA-IR比较,差异均无统计学意义(均P > 0.05);治疗后三组BMI、FPG、2hPBG、HbA1c、HOMA-IR均较治疗前降低,且治疗后C组的BMI、FPG、2hPBG、HbA1c、HOMA-IR均低于A、B组,差异均有统计学意义(均P < 0.05);三组不良反应发生率比较,差异无统计学意义(P > 0.05)。 结论 对二甲双胍无效的老年T2DM患者实施地特胰岛素联合利拉鲁肽治疗可显著降低BMI,改善糖代谢指标,效果明显优于单独使用,且安全。
[关键词] 地特胰岛素;利拉鲁肽;二甲双胍;老年人;2型糖尿病
[中图分类号] R587.1 [文献标识码] A [文章编号] 1673-7210(2020)07(c)-0074-04
Curative effect of Insulin Ditel combined with Lialuru Peptide on type 2 diabetes in elderly patients with Metformin - resistant
ZHANG Jidong1 RONG Chao1 HU Juan2 SUN Xuju3
1.Department of Pharmacy, Huazhong University of Science and Technology Hospital, Hubei Province, Wuhan 430074, China; 2.Department of Surgical, Huazhong University of Science and Technology Hospital, Hubei Province, Wuhan 430074, China; 3.Department of Pharmacy, Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Hubei Province, Wuhan 430074, China
[Abstract] Objective To investigate the effect of Insulin Ditel combined with Lialuru Peptide on Metformin - resistant elderly patients with type 2 diabetes mellitus (T2DM). Methods From October 2017 to April 2019, the clinical data of 127 elderly patients with T2DM who failed to respond to Metformin treated in Huazhong University of Science and Technology Hospital were retrospectively analyzed. According to the treatment methods, the patients were divided into group A (40 cases treated with Insulin Ditel), group B (41 cases treated with Lialuru Peptide) and group C (46 cases treated with Insulin Ditel combined with Lialuru Peptide). The changes of body mass index (BMI), fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPBG), glycosylated hemoglobin (HbA1c), insulin resistance index (HOMA-IR) among the three groups were compared before and after treatment and the adverse reactions were compared among three groups. Results There were no significant differences in BMI, FPG, 2hPBG, HbA1c and HOMA-IR among the three groups before treatment (P > 0.05). After treatment, BMI, FPG, 2hPBG, HbA1c and HOMA-IR in the three groups were lower than those before treatment, and BMI, FPG, 2hPBG, HbA1c and HOMA-IR in group C were lower than those in group A and group B after treatment, with statistically significant differences (all P < 0.05). There was no significant difference in the incidence of adverse reactions among the three groups (P > 0.05). Conclusion In the elderly T2DM patients with Metformin-resistant, the combination of Insulin Ditel and Lialuru Peptide can significantly reduce BMI and improve the index of glucose metabolism, the effect is better than that of using alone, and it is safe.
[Key words] Insulin Ditel; Lialuru Peptide; Metformin; Elderly; Type 2 diabetes
2型糖尿病(type 2 diabetes mellitus,T2DM)是常见的一种慢性疾病,资料显示,该病患者占糖尿病患者的85%左右,其中老年患者占T2DM患者的20%以上[1-2]。目前临床尚无治疗老年T2DM的统一方法,临床上多采用降糖的治疗方式。二甲双胍是治疗老年T2DM的常规药物,但是部分患者对二甲双胍无明显效果。地特胰岛素和利拉鲁肽均是老年T2DM患者的常用药物,均有降低胰岛素抵抗、控制体重的作用[3-4]。地特胰岛素、利拉鲁肽在应用二甲双胍降糖效果不佳的T2DM患者中治疗已有较多报道[5-7],但是效果仍需进一步提高。且关于地……